FLT3 and acute myeloid leukemia: FLT3 mutation is the most frequent genetic alteration in AML, with FLT3 internal tandem duplication occurring in ≈25% of adult AML patients and conferring poor overall survival and high rates of treatment resistance development.[121, 122] FLT3 inhibitors, including sunitinib, pexidartinib, midostaurin, lestaurtinib, crenolanib, and gilteritinib, synergized with CC‐90009 to reduce viability in FLT3‐ internal tandem duplication AML cell lines.